NO20052074L - Substituerte benzoksazinoner og anvendelser derav. - Google Patents

Substituerte benzoksazinoner og anvendelser derav.

Info

Publication number
NO20052074L
NO20052074L NO20052074A NO20052074A NO20052074L NO 20052074 L NO20052074 L NO 20052074L NO 20052074 A NO20052074 A NO 20052074A NO 20052074 A NO20052074 A NO 20052074A NO 20052074 L NO20052074 L NO 20052074L
Authority
NO
Norway
Prior art keywords
substituted benzoxazinones
formula
benzoxazinones
methods
provides
Prior art date
Application number
NO20052074A
Other languages
English (en)
Inventor
Shu-Hai Zhao
Hans Maag
Meng Sui
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20052074L publication Critical patent/NO20052074L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Legemiddel Substituerte benzoksazinoner og anvendelser derav. Oppfinnelsen tilveiebringer en forbindelse med formel (1): og farmasøytisk akseptable salter eller prodrug derav, hvor Y, Z, R', R'^, r\ R\ R^, R* , R^, R*, R^, m, n, p og q er som definert her. Oppfinnelsen tilveiebringer også metoder for fremstilling av, preparater omfattende og metoder for anvendelse av Forbindelser med formel (I).
NO20052074A 2002-11-08 2005-04-27 Substituerte benzoksazinoner og anvendelser derav. NO20052074L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42494602P 2002-11-08 2002-11-08
PCT/EP2003/012278 WO2004041792A1 (en) 2002-11-08 2003-11-04 Substituted benzoxazinones and uses thereof

Publications (1)

Publication Number Publication Date
NO20052074L true NO20052074L (no) 2005-06-01

Family

ID=32312902

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052074A NO20052074L (no) 2002-11-08 2005-04-27 Substituerte benzoksazinoner og anvendelser derav.

Country Status (28)

Country Link
US (1) US7141562B2 (no)
EP (1) EP1562918B1 (no)
JP (1) JP4401297B2 (no)
KR (1) KR100683361B1 (no)
CN (1) CN100390157C (no)
AR (1) AR042002A1 (no)
AT (1) ATE384054T1 (no)
AU (1) AU2003293653B2 (no)
BR (1) BR0315302A (no)
CA (1) CA2505334A1 (no)
DE (1) DE60318733T2 (no)
DK (1) DK1562918T3 (no)
ES (1) ES2298609T3 (no)
GT (1) GT200300241A (no)
HR (1) HRP20050390A2 (no)
IL (1) IL168343A (no)
MX (1) MXPA05004758A (no)
MY (1) MY136824A (no)
NO (1) NO20052074L (no)
NZ (1) NZ539508A (no)
PA (1) PA8587501A1 (no)
PE (1) PE20040828A1 (no)
PL (1) PL377770A1 (no)
PT (1) PT1562918E (no)
RU (1) RU2328490C2 (no)
TW (1) TWI285639B (no)
WO (1) WO2004041792A1 (no)
ZA (1) ZA200503248B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE424825T1 (de) 2001-07-20 2009-03-15 Psychogenics Inc Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
BRPI0308696B8 (pt) 2002-03-27 2021-05-25 Axovant Sciences Gmbh composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
ES2291984T3 (es) * 2003-12-09 2008-03-01 F. Hoffmann-La Roche Ag Derivados de benzoxazina y su empleo.
CN102114244A (zh) * 2004-09-30 2011-07-06 弗·哈夫曼-拉罗切有限公司 治疗认知障碍的组合物和方法
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
BRPI0613430A2 (pt) * 2005-07-13 2011-01-11 Hoffmann La Roche compostos derivados de benzimidazol, uso dos mesmos, método para a preparação destes e composição farmacêutica
WO2007032572A1 (en) * 2005-09-15 2007-03-22 Korea Reserach Institute Of Chemical Technology N-substituted-1h-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same
TWI385161B (zh) * 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
CA2658959A1 (en) * 2006-06-23 2007-12-27 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
ITMI20131782A1 (it) * 2013-10-25 2015-04-26 Dipharma Francis Srl Procedimento per la preparazione di un agonista della trombopoietina
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
RU2624978C2 (ru) * 2015-07-27 2017-07-11 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ лечения умеренного когнитивного снижения
MX2020001311A (es) * 2017-08-07 2020-03-20 Suven Life Sciences Ltd Compuestos de fluoropiperidina como antagonistas del receptor 5-hidroxitriptamina 6 puro.
CN111559990B (zh) * 2020-05-29 2021-03-09 四川大学华西医院 一种小分子噁噻嗪类衍生物及其应用
CN112047898A (zh) * 2020-10-14 2020-12-08 兰州大学 一种苯并[c][1,2]噁嗪骨架类新化合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU784769A3 (ru) * 1977-03-17 1980-11-30 Шел Интернэшнл Рисерч Маатсхаппии Б.В. (Фирма) Способ получени бензоксазинкарбоксамидов
DE3586794T2 (de) * 1984-12-21 1993-05-27 Duphar Int Res Arzneimittel mit psychotroper wirkung.
AU605304B2 (en) * 1987-06-22 1991-01-10 Nihon Tokushu Nayaku Seizo K.K. Benzo-fused cyclic compounds
FR2667068B1 (fr) * 1990-09-26 1994-09-09 Adir Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5955470A (en) * 1991-06-11 1999-09-21 Merrell Pharmaceuticals, Inc. Derivatives of amide analogs of certain methano bridged quinolizines
DE69736704T2 (de) * 1996-03-29 2007-09-13 Duphar International Research B.V. Piperazin- und piperidin- derivate
DE69819266T2 (de) * 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
AU772189B2 (en) * 1999-08-23 2004-04-08 Solvay Pharmaceuticals B.V. New phenylpiperazines
WO2001057003A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
EP1268452A1 (en) 2000-03-24 2003-01-02 Millenium Pharmaceuticals, Inc. BICYCLIC SULFONYL AMINO INHIBITORS OF FACTOR Xa
DE10031391A1 (de) 2000-07-03 2002-02-07 Knoll Ag Bicyclische Verbindungen und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie
ES2280417T3 (es) * 2000-10-26 2007-09-16 Smithkline Beecham Plc Derivados de benzoxazinona, su preparacion y uso.
HRP20040090A2 (en) * 2001-08-10 2004-12-31 Hoffmann La Roche Arylsulfonyl derivatives with 5-ht<sub>6</sub> receptor affinity
HRP20041030B1 (hr) * 2002-05-13 2013-03-31 F. Hoffmann - La Roche Ag Derivati benzoksazina kao regulatori 5-ht6 i njihova upotreba

Also Published As

Publication number Publication date
WO2004041792A1 (en) 2004-05-21
ES2298609T3 (es) 2008-05-16
KR20050072479A (ko) 2005-07-11
NZ539508A (en) 2007-05-31
BR0315302A (pt) 2005-08-23
PA8587501A1 (es) 2004-05-26
DK1562918T3 (da) 2008-05-05
CN100390157C (zh) 2008-05-28
KR100683361B1 (ko) 2007-02-15
DE60318733D1 (de) 2008-03-06
JP4401297B2 (ja) 2010-01-20
AU2003293653B2 (en) 2009-05-14
TWI285639B (en) 2007-08-21
RU2005117965A (ru) 2006-01-27
PE20040828A1 (es) 2004-11-25
CN1723205A (zh) 2006-01-18
AR042002A1 (es) 2005-06-08
US7141562B2 (en) 2006-11-28
JP2006514615A (ja) 2006-05-11
IL168343A (en) 2010-05-31
GT200300241A (es) 2004-06-03
AU2003293653A1 (en) 2004-06-07
PT1562918E (pt) 2008-03-12
EP1562918B1 (en) 2008-01-16
TW200418846A (en) 2004-10-01
ATE384054T1 (de) 2008-02-15
DE60318733T2 (de) 2009-01-15
MXPA05004758A (es) 2005-08-02
US20040092512A1 (en) 2004-05-13
PL377770A1 (pl) 2006-02-20
MY136824A (en) 2008-11-28
EP1562918A1 (en) 2005-08-17
ZA200503248B (en) 2006-02-22
CA2505334A1 (en) 2004-05-21
HRP20050390A2 (en) 2006-12-31
RU2328490C2 (ru) 2008-07-10

Similar Documents

Publication Publication Date Title
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
NO20083434L (no) Benzamid- og heteroarenderivater
WO2004056786A3 (en) Pyrimidine derivates for the treatment of abnormal cell growth
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
WO2007084728A3 (en) 2-imino-benzimidazoles
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
WO2003082205A3 (en) Compounds and methods
NO20015172L (no) 1-metyl-erytromycin-derivater
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
NO20040881L (no) Orale antidiabetes midler.
DK1181299T3 (da) C-2-modificerede erythromycinderivater
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
MXPA05011176A (es) Derivados de carboxamida como agentes antidiabeticos.
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
NO20062491L (no) Benzoksazinderivter og deres anvendelse
MY138826A (en) 2,7-substituted indoles
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
MXPA04006041A (es) Antivirales de piridoquinoxalina.
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
NO20071616L (no) Benzoksazin- og kinoksalinderivater og anvendelser
WO2005053702A3 (en) Anti-inflammatory agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application